Table 1.

Current state of MEK inhibitor trials in neurofibromatosis type 1

MEK inhibitor	FDA approved indication	NF‐focused trial	Status
Binimetinib	Melanoma	Phase II, LGG and PN	Ongoing
Cobimetinib	Melanoma	None	None
Mirdametinib	None/Orphan Drug Status	Phase II, PN	Completed, Weiss (2018)
Selumetinib	None/Orphan Drug Status	Phase I/II, LGG and PN	Dombi (2016); Gross (2018); Fangusaro (2019)
Trametinib	Melanoma	Phase II, PNs	McCowage (2018)

Abbreviations: FDA, Food and Drug Administration; LGG, low‐grade glioma; NF, neurofibromatosis; PN, plexiform neurofibroma.